Headache prevalence in transgender and gender diverse youth: A single‐center case–control study
Headache: The Journal of Head and Face Pain · 2023
DOI: 10.1111/head.14493 ↗Kurz gefasst
Fachartikel in der Zeitschrift Headache: The Journal of Head and Face Pain, 2023. Verfasst von Jennifer A Hranilovich und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Child Neurology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Transgender Persons. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NIDDK NIH HHS, NCRR NIH HHS.
Abstract (Originalsprache)
Objective
Assess the prevalence of headache in transgender and gender‐diverse adolescents, comparing prevalence with and without exposure to gender‐affirming hormone therapy.
Background
Transgender and gender‐diverse youth are an understudied group in whom we can study the effects of sex steroids on adolescents’ development of headache. We hypothesized that transfeminine adolescents treated with estrogen would have higher odds of headache than those not treated, and that transmasculine adolescents treated with testosterone would have lower odds of headache than those not treated.
Methods
This retrospective case–control study analyzed all patients seen at the Boston Children's Hospital Gender Multispecialty Service clinic from 2007 to 2017. Cases were defined as patients with headache, controls as those without headache, and exposure as treatment with gender‐affirming hormone therapy (i.e., estrogen or testosterone). A computerized search identified cases that were then validated by chart review.
Results
Fifty‐two of the 763 transgender and gender‐diverse patients seen were confirmed to have headache. Of 273 transfeminine patients 45% (123/273) received estrogen treatment. Transfeminine patients receiving estrogen were more likely to have headache than those not receiving estrogen (7% [9/123] vs. 1% [2/150]; odd ratio [OR] 5.84 (95% confidence interval [CI] 1.24–27.6), p = 0.026). Of 490 transmasculine patients, 46% (227/490) received testosterone. Transmasculine patients receiving testosterone were more likely to have headache than those not receiving testosterone (12% [28/227] vs. 5% (13/263); OR 2.71 (95% CI 1.37–5.4), p = 0.005).
Conclusion
Among transfeminine and transmasculine youth, those who received gender‐affirming hormone therapy had higher odds of headache compared to those not taking gender‐affirming hormone therapy. Further prospective studies to guide headache care of transgender and gender‐diverse youth and adults are needed. Our results could be generalizable to other pediatric gender management clinics and may be worth discussing with patients considering treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Child Neurology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
- Division of Endocrinology, Department of Pediatrics, Hasbro Children's Hospital, Providence, Rhode Island, USA.
- Department of Pediatrics, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
ORCID-Profile: Jennifer A Hranilovich
Förderung
- NINDS NIH HHS
- NIDDK NIH HHS
- NCRR NIH HHS
- National Institutes of Health
Zitieren
APA
Hranilovich, J. A., & Millington, K. (2023). Headache prevalence in transgender and gender diverse youth: A single‐center case–control study. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14493
Vancouver
Hranilovich JA, Millington K. Headache prevalence in transgender and gender diverse youth: A single‐center case–control study. Headache: The Journal of Head and Face Pain. 2023. doi:10.1111/head.14493
BibTeX
@article{Hranilovich2023,
author = {Hranilovich, Jennifer A and Millington, Kate},
title = {Headache prevalence in transgender and gender diverse youth: A single‐center case–control study},
journal = {Headache: The Journal of Head and Face Pain},
year = {2023},
doi = {10.1111/head.14493}
}
EUVIMED